Renato Erzen

Renato Erzen

Auto-generated profile, based on publicly available information

Renato Erzen

University Clinic of Respiratory and Allergic Diseases Golnik Golnik Slovenia

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Contact Dermatitis
Verified
Journal Article
Open access
Mojca Bizjak-SuranMojca Bizjak-Suran
Mojca Bizjak-Suran
KAKatja Adamič
Katja Adamič
NBNissera Bajrovič
Nissera Bajrovič
RERenato Eržen
Renato Eržen
MJMaja Jošt
Maja Jošt
Dejan DinevskiDejan Dinevski
Dejan Dinevski
Background: The European baseline series (EBS) of contact allergens is subject to change. An allergen is considered for inclusion when routine patch testing of patients with suspected contact dermatitis results in ≥0.5% prevalence rate.Objectives: We aimed to determine the frequency of sensitizations to 30 EBS allergens and 10 locally added allergens. Additionally, we assessed the strength and evolution of reactions to all tested allergens and co‐reactivity of additional allergens.Methods: Patch testing with our baseline series of 40 allergens was done in 748 consecutive adults. Tests were applied to the upper back and removed by patients after 48 h. Readings were done on Day 3 (D3) and D6 or D7 (D6/7). Positive reactions fulfilled the criteria of at least one plus (+) reaction. A retrospective analysis was done.Results: Eight allergens not listed in the EBS had ≥0.5% prevalence rate (i.e., cocamidopropyl betaine, thiomersal, disperse blue mix 106/124, 2‐bromo‐2‐nitropropane‐1,3‐diol, diazolidinyl urea, propylene glycol, Compositae mix II and dexamethasone‐21‐phosphate), and 16.6% of positive reactions would have been missed without D6/7 readings.Conclusion: We propose further studies to evaluate whether cocamidopropyl betaine, disperse blue mix 106/124, 2‐bromo‐2‐nitropropane‐1,3‐diol, diazolidinyl urea and Compositae mix II need to be added to the EBS.

1 June 2009 in Wiener klinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
RERenato Eržen
Renato Eržen
PKPeter Korošec
Peter Korošec
MŠMira Šilar
Mira Šilar
EMEma Mušič
Ema Mušič
MKMitja Košnik
Mitja Košnik

1 February 2002
Verified
Journal Article
Closed access
MKMitja Košnik
Mitja Košnik
PKPeter Korošec
Peter Korošec
MSMira Silar
Mira Silar
EMEma Music
Ema Music
RERenato Erzen
Renato Erzen

1 January 2006 in Scandinavian Journal of Infectious Diseases
Verified
Journal Article
Closed access
PKPeter Korošec
Peter Korošec
MSMira Silar
Mira Silar
RERenato Erzen
Renato Erzen
MKMitja Košnik
Mitja Košnik
The aim of our study was to establish the sensitivity of Legionella DNA detection in lower respiratory tract samples in 3 cases of Legionnaires' disease after initiation of specific antibiotic therapy. The results showed that Legionella amplicon intensity was highest in the sputum or bronchial aspirates collected at or before the start of appropriate therapy and decreased markedly within 3 days of therapy. PCR testing was negative within 4 to 6 days of therapy. These data suggest that within a few days specific antimicrobial therapy induces a significant drop of bacterial concentration in respiratory secretions reaching the detection limit of PCR assay. Respiratory samples for Legionella PCR should be obtained before or early after initiating antimicrobial therapy.

5 August 2021 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
RERenato Erzen
Renato Erzen
AKAna Koren
Ana Koren
JSJulij Selb
Julij Selb
NBNissera Bajrovic
Nissera Bajrovic
NLNika Lalek
Nika Lalek
MKMitja Kosnik
Mitja Kosnik